Researchers at Children’s Hospital of Philadelphia (CHOP) have developed advanced generations of adeno-associated viral (AAV) ...

Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the ...

A town hall-style meeting held last week in Cadillac to discuss PFAS contamination in the groundwater generated a number of ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced key updates on its RESET-Myositis trial and plans for the ...

The blacklegged tick is perhaps the biggest threat because it’s the only tick species that can transmit Lyme disease, a ...

A new study published in Aging Cell has identified a promising molecule that may help reverse cognitive decline associated ...

Stockholders that have previously tendered their shares must re-tender their shares Stockholders may elect to receive either $3.00 per share plus CVR of $6.84 per share in cash payable upon achievemen ...

Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass., May ...

In addition to complementing AAV manufacturing, the company’s Plasmid DNA (pDNA) platform is now available as a standalone service.

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and productivity of its proprietary ...

VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and productivity of its proprietary ...